Entera Bio Ltd.
ENTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.43 | 0.06 | 0.38 | 0.47 |
| FCF Yield | -8.55% | -42.10% | -59.66% | -12.32% |
| EV / EBITDA | -7.49 | -0.77 | -0.68 | -4.04 |
| Quality | ||||
| ROIC | -114.32% | -82.72% | -110.03% | -52.85% |
| Gross Margin | 4.97% | 0.00% | -23.13% | 34.68% |
| Cash Conversion Ratio | 0.71 | 0.82 | 0.96 | 0.74 |
| Growth | ||||
| Revenue 3-Year CAGR | 10.54% | -100.00% | -28.40% | 829,519.02% |
| Free Cash Flow Growth | 6.91% | 41.60% | -38.17% | 14.42% |
| Safety | ||||
| Net Debt / EBITDA | 0.88 | 1.21 | 0.95 | 2.02 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -421.28 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -26.03 | -540.98 | 632.47 | -45.46 |